What is Cytek Biosciences, Inc.'s EBITDA margin?

Cytek Biosciences, Inc. (CTKB) reported EBITDA margin of -17.8% in Q1 2026.

What is the long-term trend for Cytek Biosciences, Inc.'s EBITDA margin?

Over 3 years (2021 to 2025), Cytek Biosciences, Inc.'s EBITDA margin has grown at a 26.1% compound annual growth rate (CAGR), from 8.1% to -16.3%.

What does EBITDA margin mean?

EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.

Cytek Biosciences, Inc. CTKB EBITDA margin

EBITDA margin at other companies

Becton, Dickinson and CompanyBDX

22.1%+0.3pp

Thermo Fisher ScientificTMO

24.2%-0.2pp

DanaherDHR

29.2%-0.9pp

Fulgent Genetics, Inc.FLGT

-25.5%+32.9pp

10x Genomics, Inc.TXG

-0.1%0.0pp

TEC

Bio-TechneTECH

23.4%-8.3pp

Other financials

Income statement

See full

Revenue$44.1M+6.5%

Gross profit$21.3M+5.4%

Operating income-$18.5M-23.3%

Net income-$18.9M-65.5%

EPS (diluted)-$0.15-66.7%

Balance sheet

See full

Cash & equivalents$31.8M-66.6%

Total debt$16.8M+40.9%

Total equity$327.6M-13.7%

Total assets$449.1M-6.9%

Cash flow

See full

Operating cash flow-$2.7M-2,089%

CapEx$2.2M+155%

Free cash flow-$4.9M-403%

Valuation

See full

Market cap$577.27M+54.5%

Enterprise value$562.23M+93.7%

P/S2.8×+0.9×

Profitability

See full

Gross margin51.7%-3.2pp

Operating margin-21.5%—

Net margin-36.2%—

FCF margin-6.2%-15.1pp

Returns & leverage

See full

Return on equity-20.9%—

Debt / equity0.1×0.0×

Current ratio4.7×-0.9×

Where this comes from

Calculated from Cytek Biosciences, Inc.’s reported figures.

ebitda/total revenue=-17.8%

Based on trailing twelve months.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s EBITDA margin?: Cytek Biosciences, Inc. (CTKB) reported EBITDA margin of -17.8% in Q1 2026.
What is the long-term trend for Cytek Biosciences, Inc.'s EBITDA margin?: Over 3 years (2021 to 2025), Cytek Biosciences, Inc.'s EBITDA margin has grown at a 26.1% compound annual growth rate (CAGR), from 8.1% to -16.3%.
What does EBITDA margin mean?: EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.